================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6 K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
EDAP TMS S.A. Files
Press release on appointment of new CFO
November 28, 2006
EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin - France
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
This report on Form 6-K with respect to the appointment of a new Chief Financial
Officer, is hereby incorporated by reference in the registration statement of
EDAP TMS S.A. on Form F-3, file number 333-136811.
================================================================================
EDAP APPOINTS SOYER CFO; ADDS TO EXECUTIVE TEAM FOR ONGOING GROWTH, EXPANSION
LYON, France, Nov. 28 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU)
treatment of prostate cancer, is pleased to announce the appointment of Eric
Soyer to the position of Chief Financial Officer. Soyer will assume the role
December 1.
"We are very pleased to appoint Mr. Soyer to the executive team of EDAP
supporting our ongoing growth programs," said Philippe Chauveau, Chairman of
EDAP. "Mr. Soyer brings a wealth of experience in Europe and the United States,
including public company expertise. We believe this appointment further enhances
the resources of this company to successfully expand HIFU technology in the
treatment of localized prostate cancer throughout Europe and other key markets
worldwide."
Soyer was previously CFO of Medica, a euro 270 million French company
operating 108 nursing home and post-care clinics throughout France and Italy.
Soyer oversaw finance, accounting and legal affairs as well as information
systems and bank relationships. Previously he was CFO and a managing director of
April Group, an insurance services business with 22 subsidiaries in France, the
UK, Spain, Germany and Italy. Soyer managed strategic direction and financial
systems for seven subsidiaries. He also oversaw 12 acquisitions driving average
annual growth greater than 30 percent over three years. Soyer has international
experience as a controller and cost accountant for Michelin Group in France, the
United States and Africa. Soyer has degrees from Clermont Management School, the
University of Kansas and the HEC Paris School of Management.
"I am pleased to join EDAP as it launches its growth strategy for delivering
HIFU to more centers and more patients in many international markets," Soyer
said. "EDAP has a strong history of success to support its growth plans, already
showing clear success since acquiring dedicated funds to support these important
programs. The opportunity to launch HIFU at many more centers throughout Europe
and other major markets is compelling for the business as well as an important
part of improving the lifestyle preserving care available to men with prostate
cancer."
The company also announced Thierry Turbant, who has filled the role of CFO,
will remain with the company as Chief Financial Controller.
Hugues de Bantel, EDAP's Chief Executive Officer, commented, "EDAP continues
to lead the launch of prostate cancer HIFU treatment in major markets around the
world. We are grateful to Mr. Turbant for his continued support of EDAP as he
has been an integral part in propelling the company through these important
phases of growth. Our growth necessitates we bring aboard more corporate
resources to support this success. Mr. Soyer brings a blend of international
finance and capital markets experience to EDAP at a time when we are embarking
on an exciting drive to build the future of this company as the clear global
leader in prostate cancer HIFU.
"EDAP continues to see clear success in key European markets in response to
our dedicated marketing efforts. We also are bringing HIFU to many other new
countries and continuing to be the primary company opening the opportunity for
HIFU to reach men in these countries seeking alternatives to the high side
effect risks of traditional therapies. We are fully engaged in developing our US
partner program and other key advances that will play an important part in
propelling HIFU forward as a mainstream medical technology of the future."
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and
clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment
of localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized prostate
cancer (stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy treatment. The
company is also developing this technology for the potential treatment of
certain other types of tumors. EDAP TMS S.A. also produces and commercializes
medical equipment for treatment of urinary tract stones using Extra-corporeal
Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Halliburton Investor Relations
at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0) 4 78 26 40
46 or see the Company's Web sites at http://www.edap-tms.com and
http://www.hifu-planet.com .
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in these forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU
treatment is in clinical trials but not yet FDA approved or marketed in the
United States.
CONTACT: EDAP TMS S.A. Halliburton Investor Relations
Blandine Confort Matt Kreps
+33 4 78 26 40 46 972 458 8000
SOURCE EDAP TMS S.A.
-0- 11/28/2006
/CONTACT: Blandine Confort of EDAP TMS S.A., +33-4-78-26-40-46; or Matt
Kreps of Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A./
/First Call Analyst: /
/FCMN Contact: /
/Web site: http://www.edap-tms.com
http://www.hifu-planet.com /
(EDAP)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: November 28, 2006
EDAP TMS S.A.
/s/HUGUES DE BANTEL
-----------------------
HUGUES DE BANTEL
CHIEF EXECUTIVE OFFICER